FAQs
Standard BioTools Inc. stock prediction for 1 year from now: $ 0.82849 (-66.66%) Standard BioTools Inc. stock forecast for 2025: $ 2.57 (3.29%) Standard BioTools Inc. stock prediction for 2030: $ 3.02 (21.41%)
Is lab a buy or sell? ›
The consensus among 2 Wall Street analysts covering (NASDAQ: LAB) stock is to Strong Buy LAB stock.
Is SLGC good stock to buy? ›
SLGC Stock Forecast FAQ
SomaLogic has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings. The average price target for SomaLogic is $2.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
What do standard BioTools do? ›
From interrogating cell function and cancer-immune cell interactions to confidently determining new biomarkers or the integrity of samples, Standard BioTools promotes the development of breakthrough medicines faster and better through the delivery of consistent, reliable and repeatable results.
What is the annual revenue of Standard BioTools? ›
Standard BioTools Financial Highlights Compared to 2022
(“SomaLogic”), total revenue for the year ended December 31, 2023 was approximately $192 million , and cash, cash equivalents, restricted cash and short-term investments at December 31, 2023 were approximately $565 million .
What is the average accuracy of weather forecast? ›
Today the accuracy is around 97%. The biggest improvements we've seen are for longer timeframes. By the early 2000s, 5-day forecasts were “highly accurate” and 7-day forecasts are reaching that threshold today. 10-day forecasts aren't quite there yet but are getting better.
What is the target price for TBBK stock? ›
Analyst Price Targets
Based on analysts offering 12 month price targets for TBBK in the last 3 months. The average price target is $50.5 with a high estimate of $55 and a low estimate of $46.
How high will EOG stock go? ›
Average Price Target
Based on 21 Wall Street analysts offering 12 month price targets for EOG Resources in the last 3 months. The average price target is $149.50 with a high forecast of $169.00 and a low forecast of $130.00. The average price target represents a 24.39% change from the last price of $120.19.
Is O Reilly stock a good investment? ›
O'Reilly Auto has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings. The average price target for O'Reilly Auto is $1,191.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
What is the former name of Standard BioTools? ›
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation , is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health.
Following a $250 million investment from Casdin Capital, LLC and Viking Global Investors LP in April 2022, Fluidigm changed its name to Standard BioTools. This change in name emphasized their mission to create a diversified, scalable innovation-focused life science tools company serving the pharma research markets.
Who invented cytof? ›
Inspired by Flow cytometry, in 2007 Scott D. Tanner built upon this ICP-MS with the first multiplexed assay using lanthanide metals to label DNA and cell surface markers.
Should you invest in Canoo stock? ›
Canoo currently has an average brokerage recommendation (ABR) of 1.29, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by seven brokerage firms. An ABR of 1.29 approximates between Strong Buy and Buy.
What is the target price for Liquidia stock? ›
The average price target for Liquidia Technologies Inc is $24.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $32.00 ,the lowest forecast is $3.00. The average price target represents 74.29% Increase from the current price of $13.77.
Is SomaLogic a good company? ›
SomaLogic Operating Co., Inc. has an employee rating of 3.2 out of 5 stars, based on 84 company reviews on Glassdoor which indicates that most employees have a good working experience there. The SomaLogic Operating Co., Inc.
Is GlycoMimetics a buy or sell? ›
GlycoMimetics has 538.69% upside potential, based on the analysts' average price target. GlycoMimetics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.
